Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology

Modern Pathology

Volumn 28, Issue 10, 2015, Pages 1360-1368

  Andrici, Juliana ^a,b   Sheen, Amy ^a,b   Sioson, Loretta ^a,b   Wardell, Kathryn ^a,b   Clarkson, Adele ^a,c   Watson, Nicole ^a   Ahadi, Mahsa S ^a,c   Farzin, Mahtab ^a,c   Toon, Christopher W ^a,b,d   Gill, Anthony J ^a,b,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d Histopath   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA 1 ASSOCIATED PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; BAP1 PROTEIN, HUMAN; TUMOR MARKER; UBIQUITIN THIOLESTERASE;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYTOLOGY; EFFUSION; EFFUSION CYTOLOGY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MESOTHELIOMA; MESOTHELIUM CELL; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TARGET CELL; VERY ELDERLY; BIOSYNTHESIS; CYTODIAGNOSIS; MIDDLE AGED; PLEURAL EFFUSION, MALIGNANT; PLEURAL NEOPLASMS; PROCEDURES; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CYTODIAGNOSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL EFFUSION, MALIGNANT; PLEURAL NEOPLASMS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE; YOUNG ADULT;

EID: 84942991527     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2015.87     Document Type: Article

References (33)

1. Murali R, Wiesner T, Scolyer RA. Tumours associated with BAP1 mutations. Pathology 2013;45:116-126.
2. Battaglia A. The importance of multidisciplinary approach in early detection of BAP1 tumor predisposition syndrome: clinical management and risk assessment. Clin Med Insights Oncol 2014;8:37.
3. Jiao Y, Pawlik TM, Anders RA et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcino-mas. Nat Genet 2013;45:1470-1473.
4. OMIM: Online Mendelian Inheritance in Man [homepage on the Internet] Baltimore: Johns Hopkins University School of Medicine; 2015 [updated 11 July 2013; cited 28 May 2015]. Available from http://omim. org/entry/614327.
5. Pilarski R, Cebulla CM, Massengill JB et al. Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome, reporting three new cases. Genes Chromosomes Cancer 2014;53:177-182.
6. Peña-Llopis S, Vega-Rubín-de-Celis S, Liao A et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 2012;44:751-759.
7. Abdel-Rahman MH, Pilarski R, Cebulla CM et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet 2011;48:856-859.
8. De La Fouchardiere A, Cabaret O, Savin L et al. Germline BAP1 mutations predispose also to multiple basal cell carcinomas. Clin Genet; e-pub ahead of print 31 July 2014; doi: 10.1111/cge.12472.
9. Testa JR, Cheung M, Pei J et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011;43:1022-1025.
10. Wadt KA, Aoude LG, Johansson P et al. A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma. Clin Genet; e-pub ahead of print 15 September 2014; doi:10.1111/cge.12501.
11. Wiesner T, Obenauf AC, Murali R et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 2011;43:1018-1021.
12. Wiesner T, Murali R, Fried I et al. A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression. Am J Surg Pathol 2012;36:818.
13. Nasu M, Emi M, Pastorino S et al. High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol 2015;10:565-576.
14. Koopmans AE, Verdijk RM, Brouwer RWW et al. Clinical significance of immunohistochemistry for detection of BAP1 mutations in uveal melanoma. Mod Pathol 2014;27:1321-1330.
15. Bott M, Brevet M, Taylor BS et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21. 1 losses in malignant pleural mesothelioma. Nat Genet 2011;43:668-672.
16. Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg 2012;1:491.
17. Van der Bij S, Koffijberg H, Burgers J et al. Prognosis and prognostic factors of patients with mesothelioma: a population-based study. Br J Cancer 2012; 107:161-164.
18. Baud M, Strano S, Dechartres A et al. Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis. J Thorac Cardiovasc Surg 2013;145:1305-1311.
19. Carbone M, Ly BH, Dodson RF et al. Malignant meso-thelioma: facts, myths, and hypotheses. J Cell Physiol 2012;227:44-58.
20. Carbone M, Emri S, Dogan AU et al. A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nat Rev Cancer 2007;7: 147-154.
21. Farzin M, Toon CW, Clarkson A et al. Loss of expression of BAP1 predicts longer survival in meso-thelioma. Pathology 2015;47:302-307.
22. Betti M, Casalone E, Ferrante D et al. Inference on germline BAP1 mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high-risk area. Genes Chromosomes Cancer 2015;54: 51-62.
23. Yoshikawa Y, Sato A, Tsujimura T et al. Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Sci 2012;103: 868-874.
24. Henderson DW, Shilkin KB, Whitaker D. Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review. Am J Clin Pathol 1998;110:397-404.
25. Husain AN, Colby T, Ordonez N et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2013;137:647-667.
26. Husain AN, Colby TV, Ordóñez NG et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothe-lioma Interest Group. Arch Pathol Lab Med 2009;133: 1317-1331.
27. Henderson DW, Reid G, Kao SC et al. Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immuno-histochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. J Clin Pathol 2013;66:847-853.
28. Shen J, Pinkus GS, Deshpande V et al. Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids. Am J Clin Pathol 2009;131:516-523.
29. Sheffield BS, Hwang HC, Lee AF et al. BAP1 immuno-histochemistry and p16 FISH to separate benign from malignant mesothelial proliferations. Am J Surg Pathol 2015;39:977-982.
30. Monaco SE, Shuai Y, Bansal M et al. The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations. Am J Clin Pathol 2011;135:619-627.
31. Kato Y, Tsuta K, Seki K et al. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol 2007;20:215-220.
32. Shi M, Fraire AE, Chu P et al. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation. Am J Surg Pathol 2011;35:878-882.
33. Lee AF, Gown AM, Churg A. IMP3 and GLUT-1 immunohistochemistry for distinguishing benign from malignant mesothelial proliferations. Am J Surg Pathol 2013;37:421-426.